Geron Corporation (NASDAQ: GERN)is a small-cap biotech developing the novel treatment imetelstat for myeloid-based malignancies with Johnson & Johnson. Despite a positive third internal reviewfor the drug in its first two proposed indications -- myelofibrosis and myelodyspastic syndromes, Geron has remained a favorite target of short-sellers.
3 Reasons This Clinical-Stage Biotech Is an Incredible Bargain
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться